Motley Fool  Jan 28  Comment 
The medical device maker moves further into testing services.
Motley Fool  Oct 22  Comment 
Revenue growth was only 5% but improving margins helped increase non-GAAP net income by 16.5%.
SeekingAlpha  Jul 23  Comment 
Natus Medical Inc. (NASDAQ:BABY) Q2 2014 Earnings Conference Call July 23, 2014 11:00 AM ET Executives James B. Hawkins – President, Chief Executive Officer & Director Jonathan A. Kennedy – Chief Financial Officer & Senior Vice...
SeekingAlpha  Jul 23  Comment 
Track how today's Stocks To Watch are performing here. To send Complete Story »
SeekingAlpha  Apr 23  Comment 
Natus Medical Incorporated (BABY) Q1 2014 Earnings Conference Call April 23, 2014 11:00 AM ET Executives James B. Hawkins – President and Chief Executive Officer Jonathan A. Kennedy – Senior Vice President Finance and Chief...


Natus Medical Incorporated (BABY) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments. The company makes these products under three divisions that focus on specific segments of the market: newborn care, hearing, and neurology. [1] Although most of the products that Natus makes are not over-the-counter, the company must go through the long and difficult process of having its products approved. This is a source of uncertainty and concern throughout the healthcare industry.

Business Growth

Since healthcare products are bought out of necessity rather than luxury, the healthcare products industry is less susceptible to recessions such as the 2008 Financial Crisis. However, the industry is subject to the rapid rise in demand following recessions. Although Natus Medical improved its revenue and operating income between 2008 and 2009 by a nominal amount, the company improved its revenue by 31% between 2009 and 2010.[2]

Key Trends and Forces

Product Development

Developing a new product is a time-consuming and costly endeavor. For healthcare products, hundreds of thousands of designs and prototypes must be screened to identify a handful of potential successes. Even fewer of these candidates are found to be acceptably effective at identifying a disease. The equipment must then pass strict safety standards in several series of clinical trials. Throughout this process, any number of failures can occur. In particular, if the FDA disapproves a certain product, the company's stock may plummet immediately since the Research and Development Expense might have potentially have 0% return on investment or even cause substantial losses.

Health insurance

Changes in health care coverage may impact sales. If an insurance program changes its policies and removes coverage for a certain treatment, less patients will elect to obtain treatment, reducing demand for healthcare equipment and reducing sales for Natus. In general, insurance programs are more likely to cover essential expenses, such as heart disease medication, and less likely to cover nonessential expenses, such as sleep disorders.


Natus has a niche in the healthcare product industry, focusing on creating equipment that detects problems most pertinent to infants. However, there is still some competition from bigger manufacturers such as JOHNSON & JOHNSON (JNJ) that make a wide variety of products. There are also a variety of smaller companies such as Welch Allyn and Astro-Med (ALOT) that compete more directly with Natus.


  1. Reuters: Company Profile - BABY
  2. Wikinvest SEC Files: BABY 2010 10-K, Item 6
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki